Kura Oncology
KURA
10.40
-0.27
-2.55%
Kura Oncology
US · KURA
#3283 by market cap
Listed 2015
10.40
-0.27
-2.55%
Live - 5344 symbols - heartbeat 517s ago
· 2026-10-08 09:59
Pre-market
10.48
-1.78%
After-hours
10.67
0.00%
- Market cap
- 925.01M
- P/E (TTM)i
- -3.09
- P/Bi
- 19.11
- EPSi
- -3.18
- Div yieldi
- 0.00%
- 52W posi
- 46%
Reader sentiment
Are you bullish or bearish on KURA?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is -1.55, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +25.24% YoY
Margins
- Gross margin
- 99.92%
- Operating margin
- -449.94%
- Net margin
- -412.95%
Key ratios & quality
- Enterprise valuei
- 268.76M
- Altman Z-Scorei
- -1.55
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | 0 | 0 | 53.88M | 67.48M |
| Gross profit | -- | -- | -- | -- | -- | 0 | 53.88M | 67.43M |
| Selling & admin expenses | 16.10M | 19.65M | 31.50M | 46.54M | 47.05M | 50.57M | 77.11M | 119.98M |
| Research & development | 46.79M | 47.83M | 60.40M | 84.72M | 92.81M | 115.24M | 169.97M | 251.07M |
| Operating profit | -62.88M | -67.48M | -91.90M | -131.26M | -139.87M | -165.80M | -193.20M | -303.63M |
| Pretax profit | -60.45M | -63.14M | -89.63M | -130.47M | -135.84M | -152.63M | -171.97M | -278.37M |
| Tax | -- | -- | -- | -- | 0 | 0 | 2.02M | 297.00K |
| Net profit | -60.45M | -63.14M | -89.63M | -130.47M | -135.84M | -152.63M | -173.98M | -278.67M |
| Basic EPS | -2 | -2 | -2 | -2 | -2 | -2 | -2 | -3 |
| Diluted EPS | -1.72 | -1.51 | -1.69 | -1.97 | -2.03 | -2.08 | -2.02 | -3.18 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 14.11M | 15.29M | 20.75M | 17.34M | 18.27M | 20.87M |
| Gross profit | 14.11M | 15.29M | -- | -- | 18.00M | 20.63M |
| Selling & admin expenses | 22.84M | 25.17M | 32.84M | 39.14M | 31.56M | 31.75M |
| Research & development | 55.97M | 62.79M | 67.91M | 64.41M | 65.26M | 61.89M |
| Operating profit | -64.70M | -72.67M | -80.00M | -86.27M | -78.82M | -73.01M |
| Pretax profit | -57.20M | -66.12M | -74.12M | -80.93M | -73.33M | -68.32M |
| Tax | 226.00K | 0 | 0 | 71.00K | 8.00K | 5.00K |
| Net profit | -57.43M | -66.12M | -74.12M | -81.00M | -73.33M | -68.33M |
| Basic EPS | -1 | -1 | -1 | -1 | -1 | -1 |
| Diluted EPS | -0.66 | -0.75 | -0.85 | -0.92 | -0.83 | -0.77 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 181.20M | 239.60M | 637.29M | 522.29M | 446.43M | 432.48M | 744.83M | 708.66M |
| Cash & ST investments | 178.99M | 236.89M | 633.32M | 517.96M | 437.99M | 423.96M | 727.40M | 667.24M |
| Inventory | -- | -- | -- | -- | -- | -- | 0 | 413.00K |
| Total assets | 182.38M | 241.97M | 647.21M | 534.05M | 456.31M | 448.94M | 760.16M | 738.36M |
| Total current liabilities | 13.62M | 15.56M | 26.02M | 22.46M | 24.06M | 35.26M | 78.71M | 116.97M |
| Short-term debt | -- | 502.00K | 5.09M | 2.26M | 2.32M | 1.51M | 4.49M | 1.28M |
| Long-term debt | 7.50M | 7.25M | 4.25M | -- | 9.16M | 9.33M | 6.92M | 9.71M |
| Total liabilities | 21,394,000.00 | 23,191,000.00 | 36,307,000.00 | 27,442,000.00 | 36,028,000.00 | 51,662,000.00 | 346,519,000.00 | 564,228,000.00 |
| Total equity | 160.99M | 218.78M | 610.91M | 506.61M | 420.28M | 397.27M | 413.64M | 174.14M |
| Retained earnings | -149.74M | -212.88M | -302.50M | -432.97M | -568.81M | -721.44M | -895.42M | -1.17B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 724.20M | 660.08M | 620.66M | 708.66M | 623.78M | 559.44M |
| Cash & ST investments | 658.19M | 630.73M | 549.67M | 667.24M | 580.82M | 519.03M |
| Inventory | -- | -- | -- | 413.00K | 843.00K | 2.49M |
| Total assets | 743.76M | 682.43M | 649.38M | 738.36M | 652.55M | 587.79M |
| Total current liabilities | 89.77M | 107.17M | 121.30M | 116.97M | 101.50M | 118.19M |
| Short-term debt | 3.83M | 4.81M | 5.77M | 1.28M | 1.28M | 5.51M |
| Long-term debt | 7.65M | 6.51M | 5.34M | 9.71M | 9.75M | 5.57M |
| Total liabilities | 379,358,000.00 | 376,939,000.00 | 406,839,000.00 | 564,228,000.00 | 544,668,000.00 | 539,360,000.00 |
| Total equity | 364.41M | 305.49M | 242.54M | 174.14M | 107.88M | 48.43M |
| Retained earnings | -952.85M | -1.02B | -1.09B | -1.17B | -1.25B | -1.32B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -48.66M | -54.76M | -69.83M | -104.55M | -110.06M | -124.82M | 134.32M | -64.06M |
| Depreciation & amortization | 10.00K | 0 | 194.00K | 558.00K | 759.00K | 849.00K | 848.00K | 1.03M |
| Free cash flow | -48.66M | -54.76M | -72.00M | -105.70M | -110.69M | -124.99M | 133.85M | -70.70M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 132.17M | 108.17M | 459.34M | 0 | 24.72M | 93.58M | 145.81M | 0 |
| Ending cash balance | 16.12M | 26.14M | 325.70M | 90.88M | 51.80M | 37.32M | 224.46M | 149.10M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -71.93M | -28.78M | -80.63M | 117.27M | -85.85M | -62.55M |
| Depreciation & amortization | 241.00K | 224.00K | 164.00K | 403.00K | 355.00K | 369.00K |
| Free cash flow | -72.22M | -30.24M | -83.19M | 114.95M | -85.98M | -63.21M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | 0 | -- | -- |
| Ending cash balance | 51.27M | 81.95M | 95.29M | 149.10M | 39.08M | 70.24M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -50.19 | -33.25 | -21.60 | -23.35 | -29.31 | -37.34 | -42.91 | -94.82 |
| ROA %i | -43.45 | -29.76 | -20.16 | -22.09 | -27.43 | -33.72 | -28.78 | -37.19 |
| ROIC %i | -49.34 | -34.04 | -21.56 | -23.04 | -29.51 | -39.07 | -45.16 | -95.59 |
| 5-year avg ROE %i | -- | -46.49 | -39.31 | -36.05 | -31.54 | -28.97 | -30.90 | -45.55 |
| EBIT margin %i | -- | -- | -- | -- | -- | -- | -316.14 | -410.27 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | 248.40 | -- |
| Current ratioi | 13.31 | 15.39 | 24.49 | 23.26 | 18.56 | 12.26 | 9.46 | 6.06 |
| Quick ratioi | 13.16 | 15.22 | 24.34 | 23.07 | 18.21 | 12.02 | 9.27 | 5.78 |
| Debt / assetsi | 4.11 | 3.20 | 2.31 | 1.29 | 3.07 | 3.83 | 2.18 | 2.77 |
| LT debt / equityi | 4.66 | 3.31 | 1.62 | 0.91 | 2.79 | 3.95 | 2.93 | 11.01 |
| Interest coveragei | -61.32 | -107.86 | -154.06 | -314.14 | -592.19 | -97.54 | -105.22 | -183.11 |
| Revenue CAGR (3Y) %i | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -41.84 | -51.11 | -65.10 | -94.82 | -124.74 | -167.71 |
| ROA %i | -28.03 | -32.93 | -38.45 | -37.19 | -42.19 | -46.73 |
| ROIC %i | -44.31 | -53.67 | -67.42 | -95.59 | -119.60 | -155.65 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -261.86 | -232.16 | -204.82 | -410.27 | -409.03 | -382.35 |
| FCF / sales %i | 162.60 | 147.53 | 79.89 | -- | -- | -- |
| Current ratioi | 8.07 | 6.16 | 5.12 | 6.06 | 6.15 | 4.73 |
| Quick ratioi | 7.88 | 5.93 | 4.83 | 5.78 | 5.81 | 4.47 |
| Debt / assetsi | 2.60 | 2.85 | 3.00 | 2.77 | 3.72 | 4.16 |
| LT debt / equityi | 4.26 | 4.80 | 5.65 | 11.01 | 21.31 | 39.12 |
| Interest coveragei | -111.07 | -121.75 | -135.80 | -183.11 | -199.88 | -207.94 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Discovery, development and commercialization of precision medicines for the treatment of cancer100.00%
Quote time 2026-10-08 09:59:52 · For reference only, not investment advice and not tailored to your situation.